Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

TxCell Enters Col-Treg into Full Development for the Rare Disease Autoimmune Uveitis

Published: Wednesday, January 08, 2014
Last Updated: Wednesday, January 08, 2014
Bookmark and Share
Col-Treg is second product candidate from TxCell’s proprietary personalized cellular immunotherapy platform – ASTrIA.

TxCell SA has announced that it has initiated a full development program with Col-Treg for the treatment of Autoimmune Uveitis. Col-Treg is TxCell’s second therapeutic candidate from its ASTrIA platform after Ovasave®, TxCell’s lead autologous Ag-Treg cell-based immunotherapy.

Autoimmune Uveitis is a serious inflammatory condition of the eye that often results in permanent vision damage. Uveitis is classified as a rare disease with a prevalence of around 35-50/100,000, with Autoimmune Uveitis constituting 80-90% of cases.

Despite its rarity, in developed countries this autoimmune disease causes 10-15% of legal blindness. The condition also leads to 30,000 new cases of blindness per year in the US alone and affects around 168,000 people in Europe.

“Though Autoimmune Uveitis is a rare disease, it is a leading cause of blindness and can take a terrible toll. Unfortunately, Autoimmune Uveitis also has very limited treatment options, and new ones are urgently needed,” said Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs of TxCell.

The current first-line treatment consists of corticosteroids, often used with antimetabolites and alkylating agents. However, there are currently no approved options for the 50% of patients that become refractory to steroid compounds. The development of Col-Treg for treatment of steroid refractory patients could bring a new therapeutic possibility for these patients.

“The launch of Col-Treg, TxCell’s second full development program, will allow TxCell to potentially create a novel, personalized cellular immunotherapy approach to reduce the terrible burden of uveitis,” said Damian Marron, Chief Executive Officer of TxCell. “The development of the approach is made possible by the breadth of TxCell’s ASTrIA technology platform. This technology is central to TxCell's strategy of targeting orphan/niche indications with poor or no treatment options.”

In recent years, a number of scientific studies have examined several experimental models of Autoimmune Uveitis. Those studies have demonstrated that the administration or induction of regulatory T (Treg) cells in vivo can be used as therapeutic tools for the control of ocular inflammation. As a result, TxCell has developed Col-Treg as a proprietary personalized cellular immunotherapy.

Col-Treg is based on the regulatory properties of autologous collagen-II specific regulatory T lymphocytes. It is specifically designed to exert its suppressive and anti-inflammatory action upon recognition of collagen-II, a protein present in the vitreous body of the eye. TxCell has already shown efficacy for Col-Treg in models of autoimmune diseases and has also shown absence of toxicity in a 6-month toxicology study performed under Good Laboratory Practices (GLP).

The first stage of the new Col-Treg program will be to complete the required pre-requisites for applying orphan drug designations in the European Union and in the United States and to prepare for a phase II proof of principle study to start in 2015.

In addition, TxCell will request Advanced Therapy Medicinal Product (ATMP) classification by the European Medicines Agency (EMA) for this new personalized cell-based product.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TxCell Signs Strategic Agreement with MaSTherCell
Agreement for European manufacturing of its cell therapy products.
Saturday, December 05, 2015
TxCell Re-acquires Full Rights to its Lead Product Ovasave®
Agreement between TxCell and Trizell to terminate the exclusive option.
Thursday, December 03, 2015
TxCell to Present its Cellular Immunotherapy Developments
Dr. Miguel Forte and Dr. Arnaud Foussat will present at three forthcoming leading cell and gene therapy and ophthalmology conferences.
Friday, September 18, 2015
TxCell Granted US Orphan Drug Designation for Col-Treg
A first-in-man clinical study is planned to start in 2016, with top line results expected end 2017.
Tuesday, September 15, 2015
TxCell Announces Publication of Preclinical Efficacy Results for Col-Treg
Results published in Investigative Ophthalmology and Visual Science (IOVS) provide details on the demonstration of Col-Treg’s therapeutic potential in autoimmune uveitis and will support its ongoing clinical development.
Thursday, September 10, 2015
TxCell Receives Fast Track Designation from FDA for Ovasave®
TxCell’s lead product designated for the treatment of moderate to severe Crohn’s disease.
Wednesday, August 05, 2015
TxCell Appoints MaSTherCell for the Manufacturing of Ovasave®
First clinical batches could be manufactured as soon as Q2 2016.
Saturday, August 01, 2015
TxCell Announces FDA Acceptance of IND for Ovasave
IND grants TxCell option of extending current phase 2b study from EU to US.
Tuesday, June 30, 2015
TxCell Announces a Temporary Partial Hold of Activities at its Pilot Manufacturing Unit
Company expects only potential limited impact on clinical product timeline.
Wednesday, June 24, 2015
TxCell: Financial Information for the First Quarter of 2015
Company reports its revenues for 1Q 2015.
Thursday, May 14, 2015
TxCell Appoints Stéphane Boissel as Chief Executive Officer
Company promotes Miguel Forte to Chief Operating Officer.
Saturday, May 02, 2015
TxCell and Trizell Amend Collaboration Agreement
Company appoints the Cell Therapy Catapult to perform process and manufacturing development.
Friday, May 01, 2015
Strengthening of Cash Position and Development of ASTrIA Product Platform
Positive results for Col-Treg, second product candidate, in an auto-immune uveitis model.
Tuesday, April 07, 2015
TxCell to Present at Upcoming US and French Investment Conferences
Conferences include Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day, New York, March 25 and the Portzamparc PEA-PME Forum, Paris, April 1.
Saturday, March 28, 2015
Key TxCell Patent to be Granted in the US for its Lead Product Ovasave®
Patent ensures protection for Ovasave® in the US until 2030 minimum.
Thursday, March 19, 2015
Scientific News
Retractable Protein Nanoneedles
The ability to control the transfer of molecules through cellular membranes is an important function in synthetic biology; a new study from researchers at Harvard’s Wyss Institute for Biologically Inspired Engineering and Harvard Medical School (HMS) introduces a novel mechanical method for controlling release of molecules inside cells.
Leukemia’s Surroundings Key to its Growth
Researchers at The University of Texas at Austin have discovered that a type of cancer found primarily in children can grow only when signaled to do so by other nearby cells that are noncancerous.
Common Cell Transformed into Master Heart Cell
By genetically reprogramming the most common type of cell in mammalian connective tissue, researchers at the University of Wisconsin—Madison have generated master heart cells — primitive progenitors that form the developing heart.
‘Smelling’ Prostate Cancer
A research team from the University of Liverpool and the University of the West of England (UWE Bristol) has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
Genetic Mutation that Prevents Diabetes Complications
The most significant complications of diabetes include diabetic retinal disease, or retinopathy, and diabetic kidney disease, or nephropathy. Both involve damaged capillaries.
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Improving Regenerative Medicine
Lab-created stem cells may lack key characteristics, UCLA research finds.
Tick Genome Reveals Secrets of a Successful Bloodsucker
NIH has announced that decipher the genome of the blacklegged tick which could lead to new tick control methods.
"Dark Side" of the Transcriptome
New approach to quantifying gene "read-outs" reveals important variations in protein synthesis and has implications for understanding neurodegenerative diseases.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!